
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11473574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiation Oncology, 2020, 15, 264.	2.7	7
2	The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiation Oncology, 2019, 14, 121.	2.7	6
3	Factors associated with a preference for disclosure of life expectancy information from physicians: a cross-sectional survey of cancer patients undergoing radiation therapy. Supportive Care in Cancer, 2019, 27, 4487-4495.	2.2	2
4	A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Japanese Journal of Clinical Oncology, 2019, 49, 57-62.	1.3	16
5	Regulatory mechanisms of hypoxiaâ€inducible factor 1 activity: Two decades of knowledge. Cancer Science, 2018, 109, 560-571.	3.9	156
6	Effect of long fasting on myocardial accumulation in 18F-fluorodeoxyglucose positron emission tomography after chemoradiotherapy for esophageal carcinoma. Journal of Radiation Research, 2018, 59, 182-189.	1.6	9
7	Quality assurance of geometric accuracy based on an electronic portal imaging device and log data analysis for Dynamic WaveArc irradiation. Journal of Applied Clinical Medical Physics, 2018, 19, 234-242.	1.9	4
8	Dosimetric advantages afforded by a new irradiation technique, Dynamic WaveArc, used for accelerated partial breast irradiation. Physica Medica, 2018, 48, 103-110.	0.7	3
9	Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation. International Journal of Clinical Oncology, 2018, 23, 608-614.	2.2	6
10	Geometric and dosimetric accuracy of dynamic tumor tracking during volumetric-modulated arc therapy using a gimbal mounted linac. Radiotherapy and Oncology, 2018, 129, 166-172.	0.6	2
11	Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. International Journal of Clinical Oncology, 2018, 23, 158-164.	2.2	9
12	Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac. Oncotarget, 2018, 9, 23628-23635.	1.8	12
13	HIF-1 maintains a functional relationship between pancreatic cancer cells and stromal fibroblasts by upregulating expression and secretion of Sonic hedgehog. Oncotarget, 2018, 9, 10525-10535.	1.8	29
14	Case Series of 23 Patients Who Developed Fatal Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381880132.	1.9	16
15	Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer. Scientific Reports, 2018, 8, 17096.	3.3	14
16	Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702). Japanese Journal of Clinical Oncology, 2018, 48, 1076-1082.	1.3	9
17	Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma. Acta Oncológica, 2017, 56, 957-962.	1.8	5
18	Development of a four-dimensional Monte Carlo dose calculation system for real-time tumor-tracking irradiation with a gimbaled X-ray head. Physica Medica, 2017, 35, 59-65.	0.7	13

#	Article	IF	CITATIONS
19	Assessment of treatment response after lung stereotactic body radiotherapy using diffusion weighted magnetic resonance imaging and positron emission tomography: A pilot study. European Journal of Radiology, 2017, 92, 58-63.	2.6	12
20	Impact of sampling interval in training data acquisition on intrafractional predictive accuracy of indirect dynamic tumorâ€ŧracking radiotherapy. Medical Physics, 2017, 44, 3899-3908.	3.0	7
21	Three-dimensional intrafractional internal target motions in accelerated partial breast irradiation using three-dimensional conformal external beam radiotherapy. Radiotherapy and Oncology, 2017, 124, 118-123.	0.6	12
22	Stereotactic body radiotherapy for de novo spinal metastases: systematic review. Journal of Neurosurgery: Spine, 2017, 27, 295-302.	1.7	121
23	Inter- and Intrafractional Variation in the 3-Dimensional Positions of Pancreatic Tumors Due to Respiration Under Real-Time Monitoring. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1204-1211.	0.8	24
24	Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV ⩾ 100 cc. Radiotherapy and Oncology, 2017, 122, 281-285.	0.6	21
25	A circadian clock gene, <scp>PER</scp> 2, activates <scp>HIF</scp> â€1 as an effector molecule for recruitment of <scp>HIF</scp> â€1α to promoter regions of its downstream genes. FEBS Journal, 2017, 284, 3804-3816.	4.7	58
26	Estimation of the shielding ability of a tungsten functional paper for diagnostic xâ€rays and gamma rays. Journal of Applied Clinical Medical Physics, 2017, 18, 325-329.	1.9	38
27	Use of a second-dose calculation algorithm to check dosimetric parameters for the dose distribution of a first-dose calculation algorithm for lung SBRT plans. Physica Medica, 2017, 44, 86-95.	0.7	13
28	UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization. Scientific Reports, 2017, 7, 6879.	3.3	53
29	Geometric and dosimetric quality assurance using logfiles and a 3D helical diode detector for Dynamic WaveArc. Physica Medica, 2017, 43, 107-113.	0.7	5
30	Estimation of lung tumor position from multiple anatomical features on 4D―CT using multiple regression analysis. Journal of Applied Clinical Medical Physics, 2017, 18, 36-42.	1.9	4
31	Evaluation of the prevalence of burnout and psychological morbidity among radiation oncologist members of the Kyoto Radiation Oncology Study Group (KROSG). Journal of Radiation Research, 2017, 58, 217-224.	1.6	22
32	Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. Journal of Radiation Research, 2017, 58, 79-85.	1.6	7
33	A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial). Japanese Journal of Clinical Oncology. 2017. 47. 277-281.	1.3	36
34	ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. PLoS ONE, 2017, 12, e0188320.	2.5	34
35	Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. Radiation Oncology Journal, 2017, 35, 368-379.	1.5	15
36	Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy. Anticancer Research, 2017, 37, 5161-5167.	1.1	13

#	Article	IF	CITATIONS
37	LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. Oncotarget, 2016, 7, 65837-65848.	1.8	35
38	Development of a fourâ€axis moving phantom for patientâ€specific QA of surrogate signalâ€based tracking IMRT. Medical Physics, 2016, 43, 6364-6374.	3.0	16
39	Multivariate analysis for the estimation of target localization errors in fiducial markerâ€based radiotherapy. Medical Physics, 2016, 43, 1907-1912.	3.0	13
40	Technical Note: Introduction of variance component analysis to setup error analysis in radiotherapy. Medical Physics, 2016, 43, 5195-5198.	3.0	4
41	Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma. International Journal of Clinical Oncology, 2016, 21, 1023-1029.	2.2	8
42	The accuracy of extracted target motion trajectories in four-dimensional cone-beam computed tomography for lung cancer patients. Radiotherapy and Oncology, 2016, 121, 46-51.	0.6	15
43	Comparative evaluation of respiratory-gated and ungated FDG-PET for target volume definition in radiotherapy treatment planning for pancreatic cancer. Radiotherapy and Oncology, 2016, 120, 217-221.	0.6	16
44	Dosimetric comparison of lung stereotactic body radiotherapy treatment plans using averaged computed tomography and end-exhalation computed tomography images: Evaluation of the effect of different dose-calculation algorithms and prescription methods. Medical Dosimetry, 2016, 41, 305-309.	0.9	6
45	Development of a gimbal-swing irradiation technique for uniform expanded-field, wedged-beam, and intensity-modulated radiation therapy. Biomedical Physics and Engineering Express, 2016, 2, 065007.	1.2	0
46	Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2NOMO prostate cancer. International Journal of Clinical Oncology, 2016, 21, 783-790.	2.2	11
47	Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma: comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A). Japanese Journal of Clinical Oncology, 2016, 46, 748-753.	1.3	24
48	Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy. International Journal of Clinical Oncology, 2016, 21, 899-908.	2.2	17
49	L-phenylalanine preloading reduces the 10B(n, α)7Li dose to the normal brain by inhibiting the uptake of boronophenylalanine in boron neutron capture therapy for brain tumours. Cancer Letters, 2016, 370, 27-32.	7.2	19
50	Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4NOMO prostate cancer. International Journal of Clinical Oncology, 2016, 21, 148-155.	2.2	14
51	Synthesis of Biocompatible Polysaccharide Analogues and Their Application to In Vivo Optical Tumor Imaging. Bulletin of the Chemical Society of Japan, 2015, 88, 792-803.	3.2	5
52	Baseline correction of a correlation model for improving the prediction accuracy of infrared markerâ€based dynamic tumor tracking. Journal of Applied Clinical Medical Physics, 2015, 16, 14-22.	1.9	9
53	PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase. Scientific Reports, 2015, 5, 15666.	3.3	11
54	Commissioning and quality assurance of Dynamic WaveArc irradiation. Journal of Applied Clinical Medical Physics, 2015, 16, 73-86.	1.9	13

#	Article	IF	CITATIONS
55	Longâ€ŧerm stability assessment of a 4D tumor tracking system integrated into a gimbaled linear accelerator. Journal of Applied Clinical Medical Physics, 2015, 16, 373-380.	1.9	11
56	Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 116-125.	1.1	135
57	Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 619-626.	0.8	22
58	Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1616-1624.	1.1	46
59	Target localization errors from fiducial markers implanted around a lung tumor for dynamic tumor tracking. Physica Medica, 2015, 31, 934-941.	0.7	13
60	A multi-centre analysis of treatment procedures and error components in dynamic tumour tracking radiotherapy. Radiotherapy and Oncology, 2015, 115, 412-418.	0.6	10
61	UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nature Communications, 2015, 6, 6153.	12.8	175
62	Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Radiotherapy for Stage I Lung Cancer. Annals of Thoracic Surgery, 2015, 99, 1122-1129.	1.3	87
63	Influence of the correlation modeling period on the prediction accuracy of infrared marker-based dynamic tumor tracking using a gimbaled X-ray head. Physica Medica, 2015, 31, 204-209.	0.7	10
64	Definitive radiotherapy for head and neck squamous cell carcinoma: update and perspectives on the basis of EBM. Japanese Journal of Clinical Oncology, 2015, 45, 235-243.	1.3	8
65	Combination of BMP-2-releasing gelatin/ $\hat{l}^2$ -TCP sponges with autologous bone marrow for bone regeneration of X-ray-irradiated rabbit ulnar defects. Biomaterials, 2015, 56, 18-25.	11.4	53
66	Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 228-236.	4.3	20
67	Effect of intrafractional prostate motion on simultaneous boost intensity-modulated radiotherapy to the prostate: A simulation study based on intrafractional motion in the prone position. Medical Dosimetry, 2015, 40, 325-332.	0.9	4
68	Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702). Radiotherapy and Oncology, 2015, 116, 276-280.	0.6	33
69	Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1NOMO Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. International Journal of Radiation Oncology Biology Physics, 2015, 93, 989-996.	0.8	350
70	Radiation sensitivity assay with a panel of patientâ€derived spheroids of small cell carcinoma of the cervix. International Journal of Cancer, 2015, 136, 2949-2960.	5.1	27
71	Development and Clinical Application of Vero4DRT System. , 2015, , 205-215.		0
72	Evaluation of dynamic tumor-tracking IMRT for patients with pancreatic cancer using gimbaled linac of vero system Journal of Clinical Oncology, 2015, 33, 481-481.	1.6	0

#	Article	IF	CITATIONS
73	The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer. Journal of Radiation Research, 2014, 55, 934-939.	1.6	20
74	Geometric and dosimetric accuracy of dynamic tumorâ€ŧracking conformal arc irradiation with a gimbaled xâ€ray head. Medical Physics, 2014, 41, 031705.	3.0	10
75	Dosimetric comparison of Acuros XB, AAA, and XVMC in stereotactic body radiotherapy for lung cancer. Medical Physics, 2014, 41, 081715.	3.0	64
76	Development of an expandedâ€field irradiation technique using a gimbaled xâ€ray head. Medical Physics, 2014, 41, 101706.	3.0	1
77	Design, development of water tank-type lung phantom and dosimetric verification in institutions participating in a phase I study of stereotactic body radiation therapy in patients with T2NOMO non-small cell lung cancer: Japan Clinical Oncology Group trial (JCOG0702). Journal of Radiation Research. 2014, 55, 600-607.	1.6	11
78	Sonicationâ€Induced Formation of Sizeâ€Controlled Selfâ€Assemblies of Amphiphilic Janusâ€Type Polymers as Optical Tumorâ€Imaging Agents. Small, 2014, 10, 3119-3130.	10.0	12
79	Intra- and interfractional variations in geometric arrangement between lung tumours and implanted markers. Radiotherapy and Oncology, 2014, 110, 523-528.	0.6	41
80	Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo. Journal of Controlled Release, 2014, 176, 1-7.	9.9	68
81	Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. European Journal of Cancer, 2014, 50, 2932-2938.	2.8	93
82	Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac. Radiotherapy and Oncology, 2014, 112, 360-364.	0.6	62
83	Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and 18F-FDG PET. European Journal of Radiology, 2014, 83, 2087-2092.	2.6	25
84	Intrafractional tracking accuracy in infrared marker-based hybrid dynamic tumour-tracking irradiation with a gimballed linac. Radiotherapy and Oncology, 2014, 111, 301-305.	0.6	29
85	Development of a dose verification system for Vero4DRT using Monte Carlo method. Journal of Applied Clinical Medical Physics, 2014, 15, 160-172.	1.9	14
86	Dosimetric impact of gold markers implanted closely to lung tumors: a Monte Carlo simulation. Journal of Applied Clinical Medical Physics, 2014, 15, 71-79.	1.9	3
87	HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Scientific Reports, 2014, 4, 3793.	3.3	94
88	Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA pulmonary adenocarcinoma: Comparison of prospective clinical trials with propensity score analysis (JCOG1313-A) Journal of Clinical Oncology, 2014, 32, 7543-7543.	1.6	1
89	Distribution patterns of metastatic pelvic lymph nodes assessed by CT/MRI in patients with uterine cervical cancer. Radiation Oncology, 2013, 8, 139.	2.7	16
90	Two cases of radiation-induced cutaneous angiosarcoma. International Cancer Conference Journal, 2013, 2, 111-115.	0.5	0

#	Article	IF	CITATIONS
91	Differences in dose-volumetric data between the analytical anisotropic algorithm and the x-ray voxel Monte Carlo algorithm in stereotactic body radiation therapy for lung cancer. Medical Dosimetry, 2013, 38, 95-99.	0.9	13
92	Evaluation of 4D dose to a moving target with Monte Carlo dose calculation in stereotactic body radiotherapy for lung cancer. Radiological Physics and Technology, 2013, 6, 233-240.	1.9	6
93	Microenvironment and Radiation Therapy. BioMed Research International, 2013, 2013, 1-13.	1.9	122
94	Feasibility evaluation of a new irradiation technique: three-dimensional unicursal irradiation with the Vero4DRT (MHI-TM2000). Journal of Radiation Research, 2013, 54, 330-336.	1.6	28
95	Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer. Journal of Radiation Research, 2013, 54, 337-343.	1.6	10
96	Interfraction variation in lung tumor position with abdominal compression during stereotactic body radiotherapy. Medical Physics, 2013, 40, 091718.	3.0	45
97	Medical Physics, 2013, 40, 091705.	3.0	52
98	Accuracy verification of infrared markerâ€based dynamic tumorâ€ŧracking irradiation using the gimbaled	3.0	44
99	Effect of audio instruction on tracking errors using a fourâ€dimensional imageâ€guided radiotherapy system. Journal of Applied Clinical Medical Physics, 2013, 14, 255-264.	1.9	3
100	Microenvironments and Cellular Characteristics in the Micro Tumor Cords of Malignant Solid Tumors. International Journal of Molecular Sciences, 2012, 13, 13949-13965.	4.1	46
101	Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors. Journal of Radiation Research, 2012, 53, 777-784.	1.6	12
102	Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature Communications, 2012, 3, 783.	12.8	149
103	Positional accuracy of novel xâ€rayâ€imageâ€based dynamic tumorâ€tracking irradiation using a gimbaled MV xâ€ray head of a Vero4DRT (MHIâ€TM2000). Medical Physics, 2012, 39, 6287-6296.	3.0	25
104	Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 453-456.	1.1	36
105	Amphiphilic Brush-Like Copolymers Involving Hydrophobic Amino Acid- and Oligopeptide-Side Chains for Optical Tumor Imaging In Vivo. Bulletin of the Chemical Society of Japan, 2012, 85, 1277-1286.	3.2	10
106	Dosimetric Advantage of Intensity-Modulated Radiotherapy for Whole Ventricles in the Treatment of Localized Intracranial Germinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, e273-e280.	0.8	15
107	Dose–Volume Metrics Associated With Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, e545-e549.	0.8	176
108	In Vivo Imaging of Brain Ischemia Using an Oxygen-Dependent Degradative Fusion Protein Probe. PLoS ONE, 2012, 7, e48051.	2.5	7

#	Article	IF	CITATIONS
109	Optimization of the x-ray monitoring angle for creating a correlation model between internal and external respiratory signals. Medical Physics, 2012, 39, 6309-6315.	3.0	13
110	<i>In vitro</i> assessment of poly(methylmethacrylate)â€based bone cement containing magnetite nanoparticles for hyperthermia treatment of bone tumor. Journal of Biomedical Materials Research - Part A, 2012, 100A, 2537-2545.	4.0	25
111	Experimental validation of heterogeneity-corrected dose-volume prescription on respiratory-averaged CT images in stereotactic body radiotherapy for moving tumors. Medical Dosimetry, 2012, 37, 20-25.	0.9	5
112	Preparation of ferromagnetic microcapsules for hyperthermia using water/oil emulsion as a reaction field. Materials Science and Engineering C, 2012, 32, 692-696.	7.3	20
113	Nonsurgical treatments for stage 0-IA squamous esophageal cancer Journal of Clinical Oncology, 2012, 30, 113-113.	1.6	0
114	A Consensus-based Guideline Defining Clinical Target Volume for Primary Disease in External Beam Radiotherapy for Intact Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 1119-1126.	1.3	56
115	Positioning accuracy of a new image-guided radiotherapy system. Medical Physics, 2011, 38, 2535-2541.	3.0	33
116	Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1352-1358.	0.8	561
117	Detection of the Onset of Ischemia and Carcinogenesis by Hypoxia-Inducible Transcription Factor-Based In Vivo Bioluminescence Imaging. PLoS ONE, 2011, 6, e26640.	2.5	8
118	Evaluation of [ <sup>125</sup> I]IPOS as a molecular imaging probe for hypoxiaâ€inducible factorâ€1â€active regions in a tumor: Comparison among singleâ€photon emission computed tomography/Xâ€ray computed tomography imaging, autoradiography, and immunohistochemistry. Cancer Science, 2011, 102, 2090-2096.	3.9	14
119	Effective encapsulation of a new cationic gadolinium chelate into apoferritin and its evaluation as an MRI contrast agent. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 638-646.	3.3	34
120	PET Imaging of Hypoxia-Inducible Factor-1-Active Tumor Cells with Pretargeted Oxygen-Dependent Degradable Streptavidin and a Novel 18F-Labeled Biotin Derivative. Molecular Imaging and Biology, 2011, 13, 1003-1010.	2.6	22
121	Influence of Side Chain Length on Fluorescence Intensity of ROMPâ€Based Polymeric Nanoparticles and Their Tumor Specificity in Inâ€Vivo Tumor Imaging. Small, 2011, 7, 3536-3547.	10.0	35
122	Highâ€Contrast Fluorescence Imaging of Tumors Inâ€Vivo Using Nanoparticles of Amphiphilic Brush‣ike Copolymers Produced by ROMP. Angewandte Chemie - International Edition, 2011, 50, 6567-6570.	13.8	73
123	Prognostic Factors in Stereotactic Body Radiotherapy for Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1104-1111.	0.8	101
124	Interfractional Reproducibility in Pancreatic Position Based on Four-Dimensional Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1567-1572.	0.8	20
125	JCOG Radiation Therapy Study Group: History and Achievements. Japanese Journal of Clinical Oncology, 2011, 41, 1241-1243.	1.3	9
126	Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy. Cancers, 2011, 3, 3610-3631.	3.7	20

127 Sterestactic Body Redictiberapy for the Lung , 2011, 267-277. 0   128 Dosimetric characterization of a multileaf collimator for a new foură/cdimensional imageă/guided 1.0 46   129 Explicitațion of yoruita microcapsules for radictiberapy from wateriol enulsion. Journal of the Ceramic 1.1 1.0   130 Regul decection of typoxia-inducible factor-1a-ctive tumours: pretargeted lenging with a protein and Molecular Imaging, 2010, 37, 1566-1574. 6.4 1.6   131 Magnetite nanoparticles with high heating efficiencies for application in the hypertherma of cancer. 7.3 1.90   132 Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticles for enhanced urour imaging in wice: Synergistic effect of folatereceptor targeting and PEOylation. Biomaterials, 2010, 31, 354-542. 1.14 68   133 Norinvastve Fracking of Donot Cell Homing by Nex-Infrared Fluorescence Imaging Shortly after Bone 2010, 31, 354-542. 3.4   134 In Vico Imaging of HF Active Tumos by an Oxygen Dependent Degradation Protein Probe with an Introve fracking of Donot Cell Homing by Nex-Infrared Fluorescence Imaging Shortly after Bone 2010, 31, 314-54 3.4   135 Sterestacts: Body Rediction Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal 2010, 40, 456-453. 3.4   136 Bear Rediction of TOC PCT Images after sterestacts: body radiation therapy for lung cancer. 845-453. 3.4   137 Fadereand Targeting of the Hyposa inductibe Facto	#	Article	IF	CITATIONS
129   Fabrication of yttria microcapaties for radiotherapy from water/of emulsion. Journal of the Ceramic   11   15     120   Society of Japan, 2010, 115, 479-482.   11   15     130   degrading in a mechanism similar to typostal-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to typostal-inducible factor-1active tumours: pretargeted imaging with a protein degrading in a mechanism similar to typostal-inducible factor-1active turopean Journal of Nuclear Medicine and Molecular imaging, 2010, 37, 1566-1574.   16     131   Magnetite nanoparticles with high heating efficiencies for application in the hyperthermia of cancer.   7.3   149     132   Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticles for enhanced tumor imaging in wice: Synergistic effect of folate-receptor targeting and PECylation. Biomaterials, 2010, 31, 934-942.   114   58     133   Noninvasive Tracking of Donor Cell Homing by Near-Infrared Pluorescence Imaging Shortly after Bone Aerow Transplantation. PLoS ONE, 2010, 5, e11114.   2.5   34     134   In Vivo Imaging of HIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   1.3   14     136   Stereostactic Booky Radiation Therapy for Lung Cancer. Achievements and Perspectives. Japanese Journal Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   1.3   80     137	127	Stereotactic Body Radiotherapy for the Lung. , 2011, , 267-277.		0
129   Society of Japain, 2010, 116, 479-452.   11   15     130   Bapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein and Molecular Imaging, 2010, 37, 1566-1574.   6.4   16     131   Magnetite nanoparticles with high heating efficiencies for application in the hyperthermia of cancer.   7.3   149     132   Englephing metathesis polymetization-based synthesis of polymetic nanoparticles for enhanced tumor imaging in vice Synthysis of folter-receptor targeting and PECylation. Biomaterials, 2010, 31, 5134-942.   11.4   58     133   Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shorthy after Bone Warrow Transplantation. PLoS ONE, 2010, 5, e11736.   12.5   17     134   In Vvo Imaging of WIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System. PLoS ONE, 2010, 5, e1174.   2.6   34     135   Stereotactic Body Badistion Therapy for Lung Cancer. Achievements and Perspectives. Japanese Journal of Clinical Oncology, 2010, 40, 846-854.   1.3   14     136   Characterization of FDG-PET Images after stereotactic body radiation therapy for Lung Cancer. Readertherapy and Oncology, 2010, 97, 200 204.   3.4   68     137   Indelequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MeedChemeComm, 2010, 1, 50.   3.4   68	128	Dosimetric characterization of a multileaf collimator for a new fourâ€dimensional imageâ€guided	3.0	46
130   degrading in a mechanism similar to hypoxia-inducible factor-lis. European Journal of Nuclear Medicine   6.4   16     131   Magnetite nanoparticles with high beating efficiencies for application in the hyperthermia of cancer.   7.3   149     132   Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticles for enhanced turnor imaging in vivo. Synergistic effect of folate-receptor targeting and PECylation. Biomaterials, 2010, 31, 534-542.   11.4   58     1330   Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone 2.5   17     1341   In Vivo Imaging of HIF-Active Turnors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System. PLoS ONE, 2010, 5, e11714.   2.6   34     135   Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal of Clinical Oncology, 2010, 40, 840-834.   1.3   14     136   Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 840-834.   1.3   80     137   Characterization of FDC-PET Images after stereotactic body radiation therapy for lung cancer.   0.6   71     138   Indolequinone-rhood conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.   145     137   Characterization of FDC-PET Images after stereotaci	129		1.1	15
131   Materials Science and Engineering C, 2010, 30, 990-996.   7.3   149     132   Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticles for enhanced tumor imaging in vivo: Synergistic effect of folate-receptor targeting and PEGylation. Biomaterials, 2010, 31, 934-942.   11.4   58     133   Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone Marrow Transplantation. PLoS ONE, 2010, 5, e11114.   2.5   17     134   In Vivo Imaging of HIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   2.5   34     135   Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal of Clinical Oncology, 2010, 40, 846-854.   1.3   14     136   A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 445-463.   1.3   80     137   Characterization of FDC-PET Images after stereotactic body radiation therapy for lung cancer. Radiotherapy and Oncology, 2010, 97, 200-204.   0.6   71     138   Indolequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.   0.7   9     139   Imaging and Targeting of the Hypoxia-inducible Factor 1-active Mi	130	degrading in a mechanism similar to hypoxia-inducible factor-11±. European Journal of Nuclear Medicine	6.4	16
132   tumor imaging in vivo: Synergistic effect of folate-receptor targeting and PECylation. Biomaterials,   11.4   58     133   Moninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone   2.5   17     134   In Vivo Imaging of HIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an   2.5   34     135   Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal   1.3   14     136   A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External   1.3   80     137   Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 846-854.   0.6   71     138   Indeceptione-rhood of PDC-PET images after stereotactic body radiation therapy for lung cancer.   0.6   71     139   Indeceptione-rhood on of PDC-PET images after stereotactic body radiation therapy for lung cancer.   0.6   71     138   Indoleguinone-rhood on Ongog, 2010, 97, 200-204.   0.7   9     139   Imaging and Targeting of the Hypoxla-Inducible Factor 1-active Microenvironment. Journal of   0.7   9     140   Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 53322 5342.   3.4   145  <	131		7.3	149
Marrow Transplantation. PLoS ONE, 2010, 5, e11114.   2.5   17     134   In Vivo Imaging of HIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   2.5   34     135   Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   1.3   14     135   Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   1.3   14     136   A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 456-463.   1.3   80     137   Characterization of FDC-PET Images after stereotactic body radiation therapy for lung cancer.   0.6   71     138   Indelequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.   3.4   68     139   Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of O.7   9     140   Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 5342.   3.4   145     141   Impact of motion velocity on fourai-6dimensional ta	132	tumor imaging in vivo: Synergistic effect of folate-receptor targeting and PEGylation. Biomaterials,	11.4	58
134   Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.   2.3   34     135   Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal   1.3   14     136   Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 846-854.   1.3   80     136   Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 456-463.   1.3   80     137   Characterization of FDC-PET Images after stereotactic body radiation therapy for lung cancer.   0.6   71     138   Indolequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.   3.4   68     139   Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of Toxicologic Pathology, 2009, 22, 93-100.   0.7   9     140   The Akt/INTOR Pathway Assures the Synthesis of HIF-11± Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 3.4   145     141   Impact of motion velocity on foura@edimensional target volumes: A phantom study. Medical Physics, 2009, 3.0   48     142   Selective Killing of Hypoxia-Inducible Factor-1a@ <sup>4</sup> Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-	133	Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone Marrow Transplantation. PLoS ONE, 2010, 5, e11114.	2.5	17
139   of Clinical Oncology, 2010, 40, 846-854.   1.3   14     136   A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 456-463.   1.3   80     137   Characterization of FDC-PET images after stereotactic body radiation therapy for lung cancer. Radiotherapy and Oncology, 2010, 97, 200-204.   0.6   71     138   Indolequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.   3.4   68     139   Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of Toxicologic Pathology, 2009, 22, 93-100.   0.7   9     140   Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 5332-5342.   3.4   145     141   Impact of motion velocity on fourâcdimensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.   3.0   48     142   Selective Killing of Hypoxia-Inducible Factor-1âC"Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.   7.0   84	134	In Vivo Imaging of HIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System. PLoS ONE, 2010, 5, e15736.	2.5	34
136Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 456-463.1.380137Characterization of FDC-PET images after stereotactic body radiation therapy for lung cancer. Radiotherapy and Oncology, 2010, 97, 200-204.0.671138Indolequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.3.468139Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of Toxicologic Pathology, 2009, 22, 93-100.0.79140Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 332-5342.3.4145141Impact of motion velocity on fourâ-climensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.3.048142Selective Killing of Hypoxia-Inducible Factor -1â-C"Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.7.084	135		1.3	14
137   Radiotherapy and Oncology, 2010, 97, 200-204.   0.6   71     138   Indolequinone-rhodol conjugate as a fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties. MedChemComm, 2010, 1, 50.   3.4   68     139   Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of Toxicologic Pathology, 2009, 22, 93-100.   0.7   9     140   Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 5332-5342.   3.4   145     141   Impact of motion velocity on fourâ€dimensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.   3.0   48     142   Selective Killing of Hypoxia-Inducible Factor : 1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.   7.0   84     142   Imaging of HIF-1-Active Tumor Hypoxia Using a Protein Effectively Delivered to and Specifically   50   50	136	Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40,	1.3	80
138   fluorescence properties. MedChemComm, 2010, 1, 50.   3.4   68     139   Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of Toxicologic Pathology, 2009, 22, 93-100.   0.7   9     140   The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Clucose- and Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 5332-5342.   3.4   145     141   Impact of motion velocity on fourâ€dimensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.   3.0   48     142   Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.   7.0   84	137		0.6	71
139   Toxicologic Pathology, 2009, 22, 93-100.   0.7   9     140   The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284, 5332-5342.   3.4   145     141   Impact of motion velocity on fourâ€dimensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.   3.0   48     142   Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.   7.0   84	138		3.4	68
140   Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284,   3.4   145     141   Impact of motion velocity on fourâ€dimensional target volumes: A phantom study. Medical Physics, 2009,   3.0   48     141   Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.   7.0   84     142   Imaging of HIF-1-Active Tumor Hypoxia Using a Protein Effectively Delivered to and Specifically   5.0   89	139	Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. Journal of Toxicologic Pathology, 2009, 22, 93-100.	0.7	9
141   36, 1610-1617.   5.0   48     142   Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.   7.0   84     148   Imaging of HIF-1-Active Tumor Hypoxia Using a Protein Effectively Delivered to and Specifically   5.0   88	140	Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry, 2009, 284,	3.4	145
Invasive and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 3433-3441.	141	Impact of motion velocity on fourâ€dimensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.	3.0	48
	142		7.0	84
	143		5.0	33

Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(l-lactic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (acid

#	Article	IF	CITATIONS
145	Measurement of Interfraction Variations in Position and Size of Target Volumes in Stereotactic Body Radiotherapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 543-548.	0.8	26
146	Usefulness of HIF-1 Imaging for Determining Optimal Timing of Combining Bevacizumab and Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 463-467.	0.8	21
147	Survey of Stereotactic Body Radiation Therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. International Journal of Radiation Oncology Biology Physics, 2009, 75, 343-347.	0.8	132
148	Ring-Opening Metathesis Polymerization-Based Synthesis of ICG-Containing Amphiphilic Triblock Copolymers for in Vivo Tumor Imaging. Bioconjugate Chemistry, 2009, 20, 511-517.	3.6	35
149	The HIF-1-active microenvironment: An environmental target for cancer therapy. Advanced Drug Delivery Reviews, 2009, 61, 623-632.	13.7	67
150	Monitoring of Biological One-Electron Reduction by <sup>19</sup> F NMR Using Hypoxia Selective Activation of an <sup>19</sup> F-Labeled Indolequinone Derivative. Journal of the American Chemical Society, 2009, 131, 15982-15983.	13.7	66
151	Initial validations for pursuing irradiation using a gimbals tracking system. Radiotherapy and Oncology, 2009, 93, 45-49.	0.6	73
152	Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. Organic and Biomolecular Chemistry, 2009, 7, 651-654.	2.8	8
153	Preparation of Size-Controlled Magnetite Nanoparticles for Hyperthermia of Cancer. Transactions of the Materials Research Society of Japan, 2009, 34, 77-80.	0.2	7
154	Protein Transduction Domain-Mediated Delivery of Anticancer Proteins. , 2009, , 297-319.		3
155	In vitro heat generation by ferrimagnetic maghemite microspheres for hyperthermic treatment of cancer under an alternating magnetic field. Journal of Materials Science: Materials in Medicine, 2008, 19, 1897-1903.	3.6	42
156	Emission under Hypoxia: Oneâ€Electron Reduction and Fluorescence Characteristics of an Indolequinone–Coumarin Conjugate. ChemBioChem, 2008, 9, 426-432.	2.6	58
157	Stereotactic Body Radiotherapy for Oligometastatic Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2008, 72, 398-403.	0.8	202
158	TSâ€l enhances the effect of radiotherapy by suppressing radiationâ€induced hypoxiaâ€inducible factorâ€l activation and inducing endothelial cell apoptosis. Cancer Science, 2008, 99, 2327-2335.	3.9	47
159	Near-Infrared Fluorescent Labeled Peptosome for Application to Cancer Imaging. Bioconjugate Chemistry, 2008, 19, 109-117.	3.6	110
160	Geometrical differences in target volumes between slow CT and 4D CT imaging in stereotactic body radiotherapy for lung tumors in the upper and middle lobe. Medical Physics, 2008, 35, 4142-4148.	3.0	56
161	Development of a threeâ€dimensionally movable phantom system for dosimetric verifications. Medical Physics, 2008, 35, 1643-1650.	3.0	18
162	Hypoxia and Hypoxia-Inducible Factor-1 Expression Enhance Osteolytic Bone Metastases of Breast Cancer. Cancer Research, 2007, 67, 4157-4163.	0.9	217

#	Article	IF	CITATIONS
163	Cervical Lymph Node Metastases: Diagnosis at Sonoelastography—Initial Experience. Radiology, 2007, 243, 258-267.	7.3	254
164	A Japan Clinical Oncology Group Trial for Stereotactic Body Radiation Therapy of Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S115-S117.	1.1	39
165	Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study. Journal of Thoracic Oncology, 2007, 2, S94-S100.	1.1	882
166	Development of a novel fluorescent imaging probe for tumor hypoxia by use of a fusion protein with oxygen-dependent degradation domain of HIF-1α. , 2007, , .		2
167	The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochemical and Biophysical Research Communications, 2007, 360, 791-796.	2.1	61
168	Development of a new concept automatic frequency controller for an ultrasmall Câ€band linear accelerator guide. Medical Physics, 2007, 34, 3243-3248.	3.0	11
169	Development of an ultrasmall C-band linear accelerator guide for a four-dimensional image-guided radiotherapy system with a gimbaled x-ray head. Medical Physics, 2007, 34, 1797-1808.	3.0	52
170	Efficacy of Mild Temperature Hyperthermia in Combined Treatments for Cancer Therapy. Thermal Medicine, 2007, 23, 103-112.	0.1	5
171	Interinstitutional Variations in Planning for Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 416-425.	0.8	47
172	Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Science, 2007, 98, 1394-1401.	3.9	45
173	Current status of stereotactic body radiotherapy for lung cancer. International Journal of Clinical Oncology, 2007, 12, 3-7.	2.2	52
174	Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. International Journal of Clinical Oncology, 2007, 12, 356-362.	2.2	68
175	Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-11± containing Pro564. FEBS Letters, 2006, 580, 5718-5722.	2.8	31
176	Vertebrate POLQ and POLÎ <sup>2</sup> Cooperate in Base Excision Repair of Oxidative DNA Damage. Molecular Cell, 2006, 24, 115-125.	9.7	119
177	Characteristics of Patients Who Developed Radiation Pneumonitis Requiring Steroid Therapy After Stereotactic Irradiation for Lung Tumors. Cancer Journal (Sudbury, Mass ), 2006, 12, 41-46.	2.0	29
178	Enzymatic Preparation of Hollow Yttrium Oxide Microspheres for In Situ Radiotherapy of Deep-Seated Cancer. Journal of the American Ceramic Society, 2006, 89, 1347-1351.	3.8	31
179	Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. International Journal of Radiation Oncology Biology Physics, 2006, 66, 271-278.	0.8	220
180	Antitumor protein therapy; Application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer, 2006, 13, 16-26.	2.9	53

#	Article	IF	CITATIONS
181	A case of metachronous bilateral Breast Cancer with bilateral radiation pneumonitis after breast-conserving therapy. Breast Cancer, 2006, 13, 313-316.	2.9	3
182	Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Physics in Medicine and Biology, 2006, 51, 5409-5417.	3.0	34
183	Optical Imaging of Tumor Hypoxia and Evaluation of Efficacy of a Hypoxia-Targeting Drug in Living Animals. Molecular Imaging, 2005, 4, 153535002005051.	1.4	89
184	Real-time Imaging of Hypoxia-inducible Factor-1 Activity in Tumor Xenografts. Journal of Radiation Research, 2005, 46, 93-102.	1.6	41
185	Treatment planning of stereotactic radiotherapy for solitary lung tumor. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1565-1571.	0.8	74
186	Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1427-1431.	0.8	646
187	Quantitation of glutathione S transferase-pi in the urine of preterm neonates. Pediatrics International, 2005, 47, 528-531.	0.5	12
188	A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Science, 2005, 96, 288-294.	3.9	22
189	Thyroid Gland Tumor Diagnosis at US Elastography. Radiology, 2005, 237, 202-211.	7.3	581
190	Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Molecular Imaging, 2005, 4, 182-93.	1.4	52
191	Current Status and Perspectives of Hyperthermia in Cancer Therapy. AIP Conference Proceedings, 2004, , .	0.4	2
192	Evaluation of Lung Injury after Three-dimensional Conformal Stereotactic Radiation Therapy for Solitary Lung Tumors: CT Appearance. Radiology, 2004, 230, 101-108.	7.3	123
193	Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. International Journal of Oncology, 2004, 25, 713.	3.3	9
194	18F-FDG and11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Annals of Nuclear Medicine, 2004, 18, 669-674.	2.2	60
195	Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer, 2004, 101, 1623-1631.	4.1	849
196	Concentrations of Pentosidine, an Advanced Glycation End-product, in Umbilical Cord Blood. Free Radical Research, 2004, 38, 691-695.	3.3	19
197	Oxidative stress in neonates: Evaluation using specific biomarkers. Life Sciences, 2004, 75, 933-938.	4.3	38
198	Effects of antioxidants and nitric oxide on TNF-α-induced adhesion molecule expression and NF-κB activation in human dermal microvascular endothelial cells. Life Sciences, 2004, 75, 1159-1170.	4.3	33

#	Article	IF	CITATIONS
199	Early treatment of urinary infection prevents renal damage on cortical scintigraphy. Pediatric Nephrology, 2003, 18, 115-118.	1.7	49
200	A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. American Journal of Kidney Diseases, 2003, 41, 1155-1162.	1.9	66
201	Medical management of congenital anomaliesof the kidney and urinary tract. Pediatrics International, 2003, 45, 624-633.	0.5	12
202	Tumor hypoxia: A target for selective cancer therapy. Cancer Science, 2003, 94, 1021-1028.	3.9	329
203	Oxidative stress and altered antioxidant defenses in children with acute exacerbation of atopic dermatitis. Life Sciences, 2003, 72, 2509-2516.	4.3	144
204	High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. Metabolism: Clinical and Experimental, 2003, 52, 1601-1605.	3.4	30
205	Formation of Advanced Glycosylation End Products and Oxidative Stress in Young Patients with Type 1 Diabetes. Pediatric Research, 2003, 54, 419-424.	2.3	75
206	Medical management of congenital anomalies of the kidney and urinary tract. Pediatrics International, 2003, 45, 624-633.	0.5	7
207	Renal aplasia is the predominant cause of congenital solitary kidneys. Kidney International, 2002, 61, 1840-1844.	5.2	82
208	Meatus tightly covered by the prepuce is associated with urinary infection. Pediatrics International, 2002, 44, 658-662.	0.5	29
209	Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1041-1046.	0.8	275
210	Radiotherapy for metastatic brain tumors(Plenary Session 8 Metastatic brain tumors : precise) Tj ETQq0 0 0 rgBT	Overlock	18 Tf 50 302
211	Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Research, 2002, 62, 2013-8.	0.9	130
212	Increased oxidative stress in childhood atopic dermatitis. Life Sciences, 2001, 69, 223-228.	4.3	136
213	Meningeal carcinomatosis in patients with Breast Cancer: Report of 8 patients. Breast Cancer, 2001, 8, 74-78.	2.9	17
214	A case of allergic reaction to surgical metal clips inserted for postoperative boost irradiation in a patient undergoing Breast-conserving therapy. Breast Cancer, 2001, 8, 90-92.	2.9	57
215	Impact of boost irradiation with surgically placed radiopaque clips on local control in breast-conserving therapy. Breast Cancer, 2001, 8, 222-228.	2.9	22
216	The use of a permanent magnetic resonance imaging system for radiotherapy treatment planning of bone metastases. International Journal of Radiation Oncology Biology Physics, 2001, 49, 605-611.	0.8	13

#	Article	IF	CITATIONS
217	The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 889-898.	0.8	209
218	Intracranial Germinoma: Radiation Therapy with Tumor Volume-based Dose Selection. Radiology, 2001, 218, 452-456.	7.3	72
219	Time Course Change of the Heat-generating Capability of Dextran Magnetite Complex (DM) in vivo Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 2001, 17, 85-91.	0.4	4
220	Stereotactic Radiotherapy Using a Stereotactic Body Frame : Research on Effective Irradiation Angle and Correcting Dose. Japanese Journal of Radiological Technology, 2001, 57, 1395-1405.	0.1	5
221	Current Status of Clinical Hyperthermic Oncology in Japan. , 2001, , 471-479.		Ο
222	Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. Kidney International, 2000, 58, 1247-1252.	5.2	30
223	Long-term results of radiation therapy for pituitary adenoma. Journal of Neuro-Oncology, 2000, 47, 79-84.	2.9	26
224	P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative. Cancer Chemotherapy and Pharmacology, 2000, 45, 362-368.	2.3	9
225	Determination of optimal radiation energy for different breast sizes using ct-simulatior in tangential breast irradiation. Breast Cancer, 2000, 7, 231-236.	2.9	7
226	Exposure to Strong Magnetic Fields at Power Frequency Potentiates X-ray-induced DNA Strand Breaks. Journal of Radiation Research, 2000, 41, 293-302.	1.6	65
227	Neoadjuvant Chemotherapy by Transcatheter Arterial Infusion Method for Uterine Cervical Cancer. Journal of Vascular and Interventional Radiology, 2000, 11, 313-319.	0.5	19
228	Evaluation of a rapid reagent strip test for the diagnosis of childhood meningitis. Pediatrics International, 1999, 41, 443-446.	0.5	2
229	Vesicoureteral reflux in male and female neonates as detected by voiding ultrasonography. Kidney International, 1999, 55, 1486-1490.	5.2	37
230	Detection of Hypoxic Cells in Murine Tumors Using the Comet Assay: Comparison with a Conventional Radiobiological Assay. Japanese Journal of Cancer Research, 1999, 90, 880-886.	1.7	5
231	Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study. Journal of Neuro-Oncology, 1999, 42, 161-167.	2.9	21
232	Salvage radiation therapy for intracranial germinoma recurring after primary chemotherapy. Journal of Neuro-Oncology, 1999, 44, 181-185.	2.9	18
233	Cytosolic/microsomal redox pathway: a reductive retention mechanism of a PET-oncology tracer, Cu-pyruvaldehyde-bis(N 4-methylthiosemicarbazone) (Cu-PTSM). Annals of Nuclear Medicine, 1999, 13, 287-292.	2.2	10
234	Surgical margin status as a cause of local failure after breast conserving therapy. Breast Cancer, 1999, 6, 93-97.	2.9	14

#	Article	IF	CITATIONS
235	Patterns of Care Study of radiation therapy for uterine cervix cancer in Japan: The influence of age on the process. International Journal of Clinical Oncology, 1999, 4, 9-16.	2.2	1
236	Primary large cell carcinoma of the submandibular gland. International Journal of Clinical Oncology, 1999, 4, 189-192.	2.2	1
237	External beam radiation therapy with or without high-dose-rate intraluminal brachytherapy for patients with superficial esophageal carcinoma. , 1999, 86, 220-228.		37
238	Differences in target outline delineation from CT scans of brain tumours using different methods and different observers. Radiotherapy and Oncology, 1999, 50, 151-156.	0.6	66
239	Clinical Results of Transcatheter Arterial Infusion for Uterine Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 97-102.	1.3	11
240	The current status of the treatment of ductal carcinoma in situ of japanese women, especially breast conserving operation in relation to the surgical margin and short term outcome. Breast Cancer, 1998, 5, 53-58.	2.9	7
241	Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. International Journal of Radiation Oncology Biology Physics, 1998, 42, 913-916.	0.8	91
242	Radiotherapy Combined with Transcatheter Arterial Infusion Chemotherapy for Locally Advanced Cervical Cancer. Acta Oncológica, 1998, 37, 143-149.	1.8	6
243	Relationship between Thermometry Results and Tumor Response in Thermoradiotherapy Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1998, 14, 162-169.	0.4	3
244	Response of Quiescent Cell Populations in Solid Tumors to Radiation or Chemotherapy. Significance of Combination with Low Temperature Hyperthermia Thermal Medicine(Japanese Journal of) Tj ETQq0 0 0 rgB	T/Oværlock	100Tf 50 377
245	Congenitally small kidneys with reflux as a common cause of nephropathy in boys. Kidney International, 1997, 52, 811-816.	5.2	60
246	The roles and controversies of radiation therapy in breast conserving therapy for breast cancer. Breast Cancer, 1997, 4, 127-133.	2.9	2
247	Clinical results of radiofrequency hyperthermia for malignant liver tumors. International Journal of Radiation Oncology Biology Physics, 1997, 38, 359-365.	0.8	76
248	An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. International Journal of Radiation Oncology Biology Physics, 1997, 37, 1107-1113.	0.8	111
249	Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control. Radiotherapy and Oncology, 1996, 40, 225-232.	0.6	70
250	Clinical results of breast conserving therapy for stage I and II breast cancers: Assessment of local recurrences in relation to surgical margins. International Journal of Clinical Oncology, 1996, 1, 170-175.	2.2	3
251	Development of an integrated radiotherapy network system. International Journal of Radiation Oncology Biology Physics, 1996, 34, 1105-1111.	0.8	16
252	Comparison ofin vivoEfficacy of Hypoxic Cytotoxin Tirapazamine and Hypoxic Cell Radiosensitizer KU-2285 in Combination with Single and Fractionated Irradiation. Japanese Journal of Cancer Research, 1996, 87, 98-104.	1.7	9

MASAHIRO HIRAOKA

#	Article	IF	CITATIONS
253	Changes in Cell Proliferative Parameters of SCCVII and EMT6 Murine Tumors after Single-dose Irradiation. Japanese Journal of Cancer Research, 1996, 87, 662-668.	1.7	7
254	A phase I and II clinical trial of a newly developed ultrasound hyperthermia system with an improved planar transducer. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1169-1175.	0.8	16
255	Research Group in Japanese Society of Hyperthermic oncology (Chairman: M. Saito) Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1996, 12, 431-436.	0.4	1
256	Left renal pelvis of male neonates is predisposed to dilatation. Pediatrics International, 1995, 37, 352-354.	0.5	4
257	Tumor Vasculature as a Target of Hyperthermia Thermal Medicine(Japanese Journal of Hyperthermic) Tj ETQq1 1	0,784314	1 rgBT /Overle
258	Additional Effect of Nicotinamide on Thermochemotherapy Using l95mPt-CDDP for Murine Solid Tumors Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1995, 11, 348-355.	0.4	0
259	Esophageal cancer treated with radiotherapy: Impact of total treatment time and fractionation. International Journal of Radiation Oncology Biology Physics, 1994, 30, 1099-1105.	0.8	65
260	Three-dimensional treatment planning for maxillary cancer using a CT simulator. International Journal of Radiation Oncology Biology Physics, 1994, 30, 979-983.	0.8	23
261	Preliminary Results of Randomized Clinical Trial of Intra-Arterial Chemotherapy Alone and Intra-Arterial Chemotherapy Combined with Hyperthermia for Malignant Liver Tumors Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1994, 10, 162-167.	0.4	0
262	A Case of Recurrent Rectal Cancer who Survived more than 5 Years Following Thermoradiotherapy Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1994, 10, 143-149.	0.4	1
263	Transcatheter arterial infusion therapy combined with radical hysterectomy in the treatment of advanced cervical cancer. CardioVascular and Interventional Radiology, 1993, 16, 14-20.	2.0	5
264	Preclinical Studies on Interstitial Hyperthermia Using Microwave Coaxial Ring-slot Applicator Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1993, 9, 115-124.	0.4	4
265	Clinical Results of Local Hyperthermia for Refractory Head and Neck Tumors Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1993, 9, 104-114.	0.4	0
266	Clinical Results of Loco-regional Hyperthermia Combined with Chemotherapy in the Treatment of Refractory tumors Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1993, 9, 9-18.	0.4	0
267	Quercetin, an Inhibitor of Heat Shock Protein Synthesis, Inhibits the Acquisition of Thermotolerance in a Human Colon Carcinoma Cell Line. Japanese Journal of Cancer Research, 1992, 83, 1216-1222.	1.7	80
268	Regional hyperthermia combined with radiotherapy in the treatment of lung cancers. International Journal of Radiation Oncology Biology Physics, 1992, 22, 1009-1014.	0.8	38
269	Hyperthermia combined with radiation therapy for primarily unresectable and recurrent colorectal cancer. International Journal of Radiation Oncology Biology Physics, 1992, 23, 759-768.	0.8	53
270	Radiofrequency hyperthermia and radiotherapy for hepatocellular carcinoma. , 1992, , 315-325.		5

#	Article	IF	CITATIONS
271	A NEW IRRADIATION TECHNIQUE USING TWIN-WEDGE FILTERS FOR TANGENTIAL BREAST TREATMENT : OPTIMIZA TION OF DOSE DISTRIBUTION BY THE TWIN-WEDGE-FIELD TECHNIQUE. Japanese Journal of Radiological Technology, 1991, 47, 1916-1924.	0.1	1
272	Effects of Tumor Necrosis Factor and Hyperthermia on Meth-A Tumors. Japanese Journal of Cancer Research, 1991, 82, 1171-1174.	1.7	4
273	Radiofrequency thermotherapy for malignant liver tumors. Cancer, 1990, 65, 1730-1736.	4.1	48
274	Thermometry Results and Tumor Response of a 430MHz Microwave Hyperthermia System (HTS-100) Using a Lens Applicator. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1990, 6, 69-77.	0.4	0
275	Histopathological changes of human tumors following thermoradiotherapy. International Journal of Radiation Oncology Biology Physics, 1989, 17, 1265-1271.	0.8	7
276	Radiofrequency (RF) capacitive hyperthermia combined with radiotherapy in the treatment of abdominal and pelvic deep-seated tumors. Radiotherapy and Oncology, 1989, 16, 139-149.	0.6	16
277	Treatment results of intracranial germinoma as a function of the irradiated volume. International Journal of Radiation Oncology Biology Physics, 1988, 15, 285-290.	0.8	142
278	Microangiographic and histologic analysis of the effects of hyperthermia on murine tumor vasculature. International Journal of Radiation Oncology Biology Physics, 1988, 15, 411-420.	0.8	50
279	Histological Changes of the Normal Liver by Local Hyperthermia. Thermal Medicine(Japanese Journal of) Tj ETQq1	1 0.7843 0.4	14 <sub>6</sub> rgBT /Ove
280	Radiofrequency capacitive hyperthermia for deep-seated tumors. I. Studies on thermometry. Cancer, 1987, 60, 121-127.	4.1	129
281	Radiofrequency capacitive hyperthermia for deep-seated tumors. II. Effects of thermoradiotherapy. Cancer, 1987, 60, 128-135.	4.1	55
282	Regional hyperthermia combined with blockade of the hepatic arterial blood flow by degradable starch microspheres in pigs. International Journal of Radiation Oncology Biology Physics, 1987, 13, 239-242.	0.8	12
283	Clinical Experiences of Thermotherapy for Malignant Liver Tumors. Thermal Medicine(Japanese Journal) Tj ETQq1 🕻	1 0.78431 0.4	.4 rgBT /Ove
284	Histopathological Studies on the Effect of Thermoradiotherapy for Human Malignant Tumors. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1987, 3, 49-61.	0.4	0
285	4. CLINICAL APPLICATION OF HYPERTHERMIA IN CANCER THERAPY : 42th Annual Meeting Symposium : Status and Problems of Hyperthermia. Japanese Journal of Radiological Technology, 1987, 43, 82-87.	0.1	0
286	Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (thermotron RF-8) in combination with radiation for cancer therapy. Cancer, 1986, 58, 1589-1595.	4.1	177
287	An agar phantom for hyperthermia. Medical Physics, 1986, 13, 396-398.	3.0	30
288	The Heating Efficacy of Radiofrequency Capacitive Heating Devices For Human Deep-seated Tumors. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1986, 2, 23-29.	0.4	2

#	Article	IF	CITATIONS
289	Histological changes of the normal liver by local hyperthermia. Thermal Medicine(Japanese Journal of) Tj ETQq1 1	0.784314 0.4	rgBT /Overlo
290	Fundamental Characteristics of 2450 MHz Microwave Heating. Thermal Medicine(Japanese Journal of) Tj ETQq0 0	0.rgBT /C	verlock 10 T
291	Deep-heating characteristics of an RF capacitive heating device. International Journal of Hyperthermia, 1985, 1, 15-28.	2.5	68
292	DEVELOPMENT OF A MULTIPLE HELICAL ARRAY APPLICATOR OF MICROWAVE FOR THE EXTENTION OF THE HOMOGENOUS HEATING AREA. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1985, 1, 61-65.	0.4	2
293	Clinical results of radiofrequency hyperthermia combined with radiation in the treatment of radioresistant cancers. Cancer, 1984, 54, 2898-2904.	4.1	116
294	Effects of Methylglyoxal Bis(guanylhydrazone) on Tumour and Skin Responses to Hyperthermia in Mice. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine, 1984, 46, 287-291.	1.0	4